IceCure Medical Ltd. has announced impressive financial results, reporting an 83% increase in U.S. sales year-over-year. The company, known for its innovative cryoablation technology, has expanded its commercial reach significantly, now operating in 21 states. This growth is a notable indicator of the company's progress and potential within the surgical and medical instruments industry.

Background

IceCure Medical Ltd. operates under the SIC classification of Surgical & Medical Instruments & Apparatus (3841). The company trades on the Nasdaq under the ticker ICCM. Recent filings include a 6-K report on November 18, 2026, and a Schedule 13G/A on November 16, 2026, among others.

What the Filing Says

The recent filing highlights the company’s achievements, stating, "U.S. sales of ProSense® and its cryoprobes doubled year over year during the first nine months of 2026 compared to the same period in 2025." Additionally, total revenues increased by approximately 26% to $2.6 million for the nine months ended September 30, 2026, up from $2.1 million in the same period in 2025.

Impact

This growth is expected to influence various stakeholders, including investors, healthcare providers, and patients. The expansion of IceCure’s commercial presence and the successful clinical trials could enhance the adoption of its ProSense® technology among physicians, thereby increasing patient access to innovative treatment options.

What's Next

The filing does not specify what happens next, but the company is likely to continue its focus on expanding its market presence and supporting its ongoing ChoICE Study, which evaluates ProSense® cryoablation for low-risk breast cancer treatment.